All Articles

Ayami Sato^1,2, Nantiga Virgona², Yuko Sekine¹ and Tomohiro Yano^2*

¹Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan
²Research Institute of Life Innovation, Toyo University, Gunma, Japan

 Malignant mesothelioma (MM) is an aggressive cancer associated with exposure to asbestos. In recent years, despite restrictions on the use of asbestos, the incidence of MM has been increasing due to its long latency period. Owing to its poor prognosis, the treatment of MM requires innovative therapies. Tocotrienol (T3), one of the vitamin E analogues, has powerful antioxidant properties and anti-cancer effects. However, these effects have not been fully understood, and are mediated independent of its antioxidant activity. Therefore, we have synthesized a new redox-inactive derivative of T3 (T3E) that has shown a stronger anti-MM effect than its redox-sensitive mother compound. In this review, we discuss the potential for anti-MM effect of T3E as non-antioxidant functions of T3 by introducing our previous reports.

Takeo Kato^1*, Minako Ide¹ and Masatoshi Nakata²

¹Department of Pediatrics, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan
²Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto Japan

 Infantile spasms (IS) is the most recognized epileptic encephalopathy in early infancy, resulting in poor cognitive outcome. Adrenocorticotropic hormone (ACTH) therapy is the first-line therapy for IS, but the relapse rate is high. Relapse after initial ACTH therapy is a poor prognostic factor for long-term seizure control and outcome of cognitive function. Recently, several studies have reported on the long-lasting maintenance of the positive effects produced by an initial course of ACTH by using long-term weekly ACTH therapy for relapsed IS. Here, we review the clinical characteristics of five previously reported cases. Epileptic spasms and hypsarrhythmia remained completely resolved during the extended ACTH therapy and did not recur after ACTH discontinuation in all cases. Furthermore, no cognitive or neurodevelopment deterioration was observed, and no serious adverse events occurred in any patient. In conclusion, this therapy appears safe and may lead to improved psychomotor development. We believe that it may be a good alternative therapy when frequent relapses occur after a favorable response to an initial course of conventional ACTH therapy. However, further studies are required to examine the risks and benefits of this therapy for relapsed IS in a large population and in countries in addition to Japan.

Patsy Thrasher¹, Mahipal Singh¹ and Krishna Singh^1,2*

¹Department of Biomedical Sciences, James H Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
²James H Quillen Veterans Affairs Medical Center, Mountain Home, TN, USA

 Ataxia-telangiectasia mutated kinase (ATM) is a serine/threonine kinase. Mutations in the ATM gene cause a rare autosomal multisystemic disease known as Ataxia-telangiectasia (AT). Individuals with mutations in both copies of the ATM gene suffer from increased susceptibility to ionizing radiation, predisposition to cancer, insulin resistance, immune deficiency, and premature aging. Patients with one mutated allele make-up ~1.4 to 2% of the general population. These individuals are spared from most of the symptoms of the disease. However, they are predisposed to developing cancer or ischemic heart disease, and die 7-8 years earlier than the non-carriers. DNA double-strand breaks activate ATM, and active ATM is known to phosphorylate an extensive array of proteins involved in cell cycle arrest, DNA repair, and apoptosis. The importance of ATM in the regulation of DNA damage response signaling is fairly well-established. This review summarizes the role of ATM in the heart, specifically in cardiac remodeling following β-adrenergic receptor stimulation and myocardial infarction.

David Badrudin, Pierre Dubé and Lucas Sideris*

Maisonneuve-Rosemont Research Center, Maisonneuve-Rosemont Hospital, Université de Montréal, Montréal QC, Canada

 Background: Cytoreductive surgery combined to hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard of care for selected patients with peritoneal surface malignancies. Preclinical studies, especially when performed on animal models, provide a framework for improvement of this treatment. This study aims to present an overview of a single institution's experience in this setting.

Methods/Results: Review of all preclinical studies from a single center was conducted using PubMed and author databases. Multiple experiments were conducted using pig and rat models. These studies examined the impact of different surgical techniques, such as the electrovaporization of tumor nodules and the use of different suture material, in the context of HIPEC. The pharmacokinetics of multiple intraperitoneal cytotoxic agents – namely oxaliplatin, raltitrexed, irinotecan and pemetrexed – were also studied.

Conclusion: Experimental studies help guide future directions for the treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy.

Michael Y. Soliman, Rima El-Abassi* and John D. England

Department of Neurology, South East Louisiana Veteran Health Care Sysytem (SELVHCS), Louisiana State University, New Orleans, Louisiana, 70112, United States

Di-Fei Lu, and Xiao-Hui Guo*

Peking University First Hospital, Beijing, China

 Polycystic ovary syndrome (PCOS) is a prevalent female endocrine and metabolic disorder, and is typically presented with menstrual irregularity and an excess of androgen production. Obesity is a common comorbidity with PCOS, and accompanying insulin resistance is proved to be a key pathogenesis of PCOS. Several parameters have been applied to evaluate obesity, including body-mass index (BMI), waist circumference (WC), percentage of body fat (PBF) and lipid accumulation product (LAP) index. Accumulating studies were conducted to analyze the association between the markers of obesity and PCOS, as well as the cut-off level of each marker in order to detect higher risk of cardiovascular diseases or rule out metabolic syndrome. However, standards of obesity parameters to screen or diagnose PCOS are yet to be established. Herein we briefly review the association of obesity measuring methods and its diagnostic value with PCOS, which gives insight into the development of standard criteria for obesity in PCOS.

Mark J C Nuijten^1,2* and Jan Vis³

¹A2M (Ars Accessus Medica), 1546 LG Amsterdam, The Netherlands
²H4V, 1546 LG Amsterdam, The Netherlands
³Talanton, Amsterdam, The Netherlands
⁴RSM, Erasmus University, Rotterdam, The Netherlands

 Rational: Many pharmaceutical companies, especially biotechnology companies, are now commercializing innovative so-called expensive medicinal products, e.g. biologicals, and especially orphan drugs, with an incremental cost-effectiveness ratio (ICER), which will probably exceed threshold values that are commonly regarded as acceptable for reimbursement.

Objective: The goal of this paper is to propose an additional methodology to evaluate and valuate innovative drugs from a broader perspective by applying concepts from business valuation, when the ICER exceeds the threshold.

Methods: Medical innovation relies on the market mechanisms in the finance market of biotechnology including the incentives of the various stakeholders, especially the capital providers, who demand a required return on investment. The justification of the orphan drug price can be based on the Discounted Cash Flow method, which is based on the expected free cash flows and the required cost of capital, and can be used to validate the price of the new drug from a narrow investor’s perspective.

Conclusion: We propose an alternative policy approach for the evaluation of ultra-innovative drugs from a broader perspective by bridging concepts from health economics and the economics of business (economic) valuation. This approach may justify a drug price, especially when ICER exceeds the threshold.

Marc Dooms*

Senior Orphan-Drug Pharmacist, University Hospitals Leuven, Belgium

Edgar M. Pera¹*, Nadège Gouignard¹ and Marco Maccarana²

¹Lund Stem Cell Center, Lund University, 221 84 Lund, Sweden
²Dept. Experimental Medical Science, Lund University, 221 84 Lund, Sweden

Musculocontractural Ehlers-Danlos syndrome (MC-EDS) is a rare recessive disorder that is characterized by connective tissue fragility, distinct craniofacial features and congenital malformations. MC-EDS patients have defects in the enzymes dermatan sulfate epimerase-1 and dermatan 4-O-sulfotransferase-1, which are involved in the biosynthesis of iduronic acid in the chondroitin sulfate/dermatan sulfate (CS/DS) chains of proteoglycans (PGs). While the connective tissue defect is a result of disturbed collagen fibril assembly based on a decreased iduronic acid content of interacting CS/DS-PGs, the cause of the developmental malformations in MC-EDS is not well understood. This review focuses on a new role of CS/DS-PGs in the development of multipotent and highly migratory neural crest (NC) cells in the Xenopus embryo model of MC-EDS. Single iduronic acid residues in CS/DS-PGs are involved in the formation of NC-derived craniofacial structures by facilitating the migration and adhesion of NC cells to fibronectin. Our results suggest a defect in NC development as cause of the craniofacial and other congenital anomalies in MC-EDS patients, which might contribute to an improved diagnosis and etiology-based therapy.

Brian Godman^1,2,3*, Isabel Frost⁴, Richard Harrington⁵ and Finlayson AE⁶

¹Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden
²Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
³Liverpool Health Economics Centre, University of Liverpool, Chatham Street, Liverpool, UK L69 7ZH
⁴Department of Zoology, University of Oxford, Oxford, OX1 3PS, United Kingdom
⁵Nuffield Department of Population Health, British Heart Foundation Centre on Population Approaches for NCD Prevention, University of Oxford, Oxford, United Kingdom
⁶Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

 There are considerable differences in how patients respond to treatments due to a number of factors calling for personalised approaches to care, which is happening. However, the early promise of personalised medicine has not always translated into improved care for patients. Payers have concerns that current tests can be costly, requests for funding specific tests have subsequently been reversed as more information becomes available, and there is currently fragmentation in the funding of diagnostic tests. Payers also have concerns that pharmaceutical companies are exploiting the situation by seeking orphan status for their new targeted medicines driving up requested prices. It is also not clear who should fund biomarkers that accompany new expensive medicines. This is changing as the cost of tests come down, and payers develop new models to optimise the managed entry of new medicines as well as evaluate potential prices for new medicines for orphan diseases. There are also developments with ‘big data’ offering new understanding of disease complexity to enhance pipeline productivity and diagnosis as well as ongoing developments with drug resistance testing and research into the role of microbiomes to improve future health. Current challenges and concerns are being addressed. This will continue to improve patient care.

Kim A Lennox and Mark A Behlke*

Integrated DNA Technologies, Inc., Coralville, IA, 52241, USA

Ralf-Dieter Hilgers^1*, FranzKönig², Geert Molenberghs³ and Stephen Senn⁴

¹Department of Medical Statistics, RWTH Universit Aachen, Pauwelstr 30, D? 52074 Aachen, Germany
²Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
³I?BioStat, Universiteit Hasselt, B?3590 Diepenbeek, Belgium
⁴Competence Centre for Methodology and Statistics, Luxembourg Institute of Health, L?1445 Strassen, Luxembourg

 The mostly unmet need as well as the pressure to show efficacy of new therapies to treat rare diseases contrasts with the limited possibility to use traditional statistical methods to design and analyse clinical trials in this setting. Within this paper, we will refer to the current state of design and analysis methods, as well as practical conditions to be considered when conducting a clinical trial for rare diseases. We will embed the research of the IDeAl project within this setting and give some first recommendations to improve the methodology for clinical trials in rare diseases.

Daniel H. Elbrecht, Christopher J. Long and James J. Hickman*

NanoScience Technology Center, University of Central Florida, Orlando, Florida, 32826, USA

 Transepithelial/endothelial electrical resistance (TEER) is a valuable method for assaying in vitro barrier tissue integrity, and is becoming an important measurement for body-on-a-chip barrier tissue devices due to its usefulness and non-invasive nature. The measurement concept is relatively straightforward, with TEER measurements performed by applying an AC electrical signal across electrodes placed on both sides of a cellular monolayer and measuring voltage and current to calculate the electrical resistance of the barrier. However, details of the setup, measurement circuit, and applied electrical signal must be properly designed for accurate measurements. Several main factors contribute to errors and variability in the measurement of TEER values, and while many of these factors can be reasonably controlled with little effort in Transwell®-type culture conditions, these factors can become major issues in body-on-a-chip devices without proper design. This mini-review outlines several important aspects of TEER measurements, including the basic theory, commercial systems used to perform measurements, major factors that contribute to measurement errors, and the application of TEER measurements to current body-on-a-chip barrier tissue devices, with the aim of providing guidance for the design of novel body-on-a-chip systems.

Louise F. Øbro¹, Katja V. Pedersen², Søren K. Lildal¹, Susanne S. Osther¹, Helene U. Jung¹, Kim H. Andreassen¹ and Palle J. S. Osther^1,*

¹Department of Urology, Urological Research Center, Lillebaelt Hospital, University of Southern Denmark, Fredericia, Denmark
²Department of Clinical Genetics, Lillebaelt Hospital, University of Southern Denmark, Vejle, Denmark

 Cystinuria is a rare genetic disorder caused by mutations in the genes that encode the two subunits of amino acid transport, resulting in failure of absorption of filtered dibasic amino acids including cystine in the proximal tubules. Despite new knowledge of the molecular basis of cystinuria, it continues to be one of the most challenging stone diseases. There is no curative treatment of cystinuria, and patients will have life-long risk of stone formation, repeated surgery, impaired renal function and quality of life. Management of cystinuria requires a multi-modal approach in dedicated centres to improve treatment outcome and patient compliance. Recent developments in cystine crystal growth inhibitors may hold promise for more effective stone prevention in the future.

Stanley T. Crooke*, Wen Shen and Xue-hai Liang

Ionis Pharmaceuticals Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA

 Human RNase H1 cleaves RNA only when the RNA is present in a DNA-RNA heteroduplex. Previous efforts to create RNase H1 knockout mice resulted in embryonic lethality1, but demonstrated that RNase H1 is required for mitochondrial function. We constructed viable constitutive hepatocyte liver specific RNase H1 knock out mice by coupling the Cre recombinase to an albumin promoter as albumin is not expressed till late in gestation. We also constructed hepatocyte specific tamoxifen inducible hepatocyte knockout mice.

Our studies demonstrate that mammalian RNase H1 is required for transcription of mitochondrial ribosomal DNA and removal of R Loops. The absence of RNase H1 leads to mitochondrial dysfunction and hepatocyte apoptosis and liver dysfunction. Subsequently, a clone of hepatocytes that lost the Cre-recombinase and thereby regained RNase H1 expression emerged, supporting the analysis of events leading to liver regeneration. RNase H1 is confirmed to be responsible for the pharmacological effects of DNA-like antisense drugs as well.

Tugba Avci*, Irfan Tasoglu, Emre Aygun and Mustafa Pac

Yuksek Ihtisas Egitim ve Arastlrma Hastanesi, Ankara, Turkey Department of Cardiovascular Surgery, Turkey

Background:There are many usage areas of the PTFE patch in cardiac surgery. In this report, we present an unusual complication which should be kept in mind about PTFE membranes.

Case presentation:The 20-year-old male patient had been operated for ascending aortic aneurysm. David Procedure was carried out. After (in)the procedure, before the sternal closure, the pericardial closure was applied with PTFE membrane to avoid the sternal adhesions. The sternal wound drainage occurred two months after the operation. After further evaluations, surgery was the choice. The cure was achieved by removing the PTFE membrane. The sternum closure was applied without pericardial closure. His wound healed fastly.

Conclusions:The complications about prosthetic materials are trouble for surgeons. In many cases, the cure is achieved by removing the prosthetic materials. In most times, radiology is helpful for diagnosis, but rarely, it might be a misleading procedure.

W.C. Aw, N. A. Youngson and J. W. O. Ballard*

School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, Australia

 Mitochondria are an important regulator of organismal fitness and the key energy converting organelle. The flow of energy in eukaryotes involves the conversion of macronutrients to form substrates that drive mitochondrial respiration. Changing the relative ratio of dietary macronutrients can influence metabolic flexibility and alter the production of mitochondrial metabolites, such as reactive oxygen species (ROS), which can influence mitochondrial functions and affect the organismal health. In this review, we describe the differences in mitochondrial output due to dietary macronutrient composition in individuals with Complex I mutations. Non-synonymous mutations in mitochondrial Complex I subunits are a common cause of early-onset mitochondrial diseases. We discuss the possibility of manipulating macronutrient ratios as a treatment for some cases of mild mitochondrial dysfunction.

Yuichiro Sakamoto*

Department of Emergency and Critical Care Medicine Faculty of Medicine, Saga University, Saga, Japan

Philippa C. Fowler#, Dwayne J. Byrne# and Niamh C. O’Sullivan*

UCD School of Biomolecular and Biomedical Sciences, UCD Conway Institute, University College Dublin, Dublin 4, Ireland

 Hereditary spastic paraplegias (HSPs) are a group of inherited neurodegenerative conditions characterised by retrograde degeneration of the longest motor neurons in the corticospinal tract, resulting in muscle weakness and spasticity of the lower limbs. To date more than 70 genetic loci have been associated with HSP, however the majority of cases are caused by mutations that encode proteins responsible for generating and maintaining tubular endoplasmic reticulum (ER) structure. These ER-shaping proteins are vital for the long-term survival of axons, however the mechanisms by which mutations in these proteins give rise to HSP remain poorly understood. To begin to address this we have characterized in vivo loss of function models of two very rare forms of HSP caused by loss of the ER-shaping proteins ARL6IP1 (SPG61) and RTN2 (SPG12). These models display progressive locomotor defects, disrupted organisation of the tubular ER and length-dependant defects in the axonal mitochondrial network. Here we compare our findings with those associated with more common forms HSP including: Spastin, Atlastin-1 and REEP 1 which together account for over half of all cases of autosomal dominant HSP. Furthermore, we discuss recent observations in other HSP models which are directly implicated in mitochondrial function and localization. Overall, we highlight the common features of our rare models of HSP and other models of disease which could indicate shared mechanisms underpinning neurodegeneration in these disorders.

Justin M. Bradley, Nick E. Le Brun and Geoffrey R. Moore*

Centre for Molecular and Structural Biochemistry, School of Chemistry, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

Karolis Jonavicius^1*, Kestutis Salcius², Raimundas Meskauskas³, Nomeda Valeviciene⁴, Virgilijus Tarutis² and Vytautas Sirvydis²

¹Faculty of Medicine, Vilnius University, Vilnius, Lithuania
²Department of Cardiovascular Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
³National Center of Pathology, Affiliate of Vilnius University Hospital Santariskiu Clinics
⁴Department of Radiology, Nuclear medicine and Physics of Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Christian Apsey and Brenda L. Bohnsack*

Kellogg Eye Center and Department of Ophthalmology and Vision Sciences, University of Michigan, Ann Arbor, Michigan 48105, USA

 Primary infantile-onset glaucoma is a rare, potentially blinding disease that is due to malformation of the trabecular meshwork and aqueous outflow tracts (goniotrabeculodysgenesis). While goniotrabeculodysgenesis is typically an isolated finding, there are reports of primary infantile-onset glaucoma in the setting of collagen disorders, specifically Stickler syndrome and osteogenesis imperfecta.

In Stickler syndrome, defects in type II or type XI collagen are commonly associated with craniofacial anomalies, hearing loss, hypermobile joints, and vitreoretinal abnormalities. Osteogenesis imperfecta is caused by disruption in type I collagen synthesis and is characterized by frequent bone fractures. Both type I and type II collagens are major structural proteins in the trabecular meshwork of the eye and both of these collagen disorders show higher incidences of adult-onset glaucoma. Herein we review the association between primary infantile-onset glaucoma and collagen disorders, which gives insight into the development of the trabecular meshwork and the aqueous outflow tracts of the eye.

Mehdi B Hamaneh and Yi-Kuo Yu*

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA

 In recent years several methods have been proposed to assign pairwise mechanism-based similarity scores to human diseases. Despite their differences in approach and performance, these methods work in a somewhat similar manner: first a set of biomolecules (genes, proteins, chemicals, etc.) is associated with each disease, and then a measure is defined to calculate the similarity between the sets assigned to a pair of diseases. Since the similarity score between two diseases is defined based on the underlying molecular processes, a high score may hint at a shared cause, and therefore a similar treatment, for both diseases. This is of great practical importance especially when a rare or newly-discovered disease, for which limited information is available, is found to be related to a disease with a known treatment. Thus, in this mini-review we briefly discuss the recently developed methods for computing mechanism-based disease-disease similarities.

Sith Siramolpiwat^1,2, Susana Seijo^3*

¹Chulabhorn International College of Medicine, Thammasat University, Pathumthani, 12120, Thailand
²Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, 12120, Thailand
³CTO, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare disorder consisting of intrahepatic portal hypertension in the absence of other identifiable intrinsic liver diseases and/or splanchnic vein thrombosis. The exact pathophysiology of INCPH is yet to be determined. This disorder is linked with several conditions such as immunological disorders, chronic infections, prothrombotic disorders, genetic predisposition and/or toxins. There is no specific positive diagnostic test. The diagnosis of INCPH is based on a high index of suspicion, a set of clinical criteria and exclusion of other causes of portal hypertension. Liver biopsy is mandatory to firmly rule out cirrhosis or other causes of liver diseases. The patency of splanchnic venous system should be also demonstrated. Most patients present with signs or symptoms of portal hypertension (i.e. gastro-esophageal varices, variceal bleeding), which should receive the same management strategy as per the current accepted guidelines in cirrhosis. The prevalence of portal vein thrombosis in INCPH ranges from 13-46%. Although liver function is usually preserved and prognosis is generally good, some patients may develop liver-related complications that would eventually require liver transplantation and/or that would overshadow long-term prognosis. 

Irene San-Román-Monserrat^1*, Juan-Ramón Gimeno-Blanes², María Elena Rodríguez-González-Herrero³, Andrea Sodi⁴, Alessandro Mecocci⁵, Marisol Alegría-Fernández⁶, David López –Cuenca⁷ and Beatriz Rodríguez-González- Herrero⁸

¹Department of Internal Medicine, Hospital General Universitario Reina Sofía, Murcia, Spain
²Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
³Department of Ophthalmology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
⁴Department of Ophthalmology, Careggi Teaching Hospital, Firenze, Italy
⁵Department of Informatics and Mathematical Sciences, Siena University, Siena, Italy
⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
⁸ENT Consultant, Hospital Comarcal del Noroeste, Caravaca, Murcia, Spain